Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E50.79 EPS (ttm)0.87 Insider Own0.20% Shs Outstand2.44B Perf Week1.07%
Market Cap108.00B Forward P/E15.50 EPS next Y2.86 Insider Trans0.00% Shs Float2.44B Perf Month3.12%
Income2.14B PEG3.88 EPS next Q0.69 Inst Own9.30% Short Float0.24% Perf Quarter4.68%
Sales37.04B P/S2.92 EPS this Y-89.20% Inst Trans3.38% Short Ratio1.92 Perf Half Y16.16%
Book/sh0.90 P/B49.21 EPS next Y1.24% ROA2.90% Target Price47.55 Perf Year4.06%
Cash/sh2.40 P/C18.42 EPS next 5Y13.10% ROE188.80% 52W Range37.20 - 45.58 Perf YTD15.01%
Dividend1.95 P/FCF636.42 EPS past 5Y-28.90% ROI8.60% 52W High-2.83% Beta1.02
Dividend %4.40% Quick Ratio0.60 Sales past 5Y0.40% Gross Margin68.40% 52W Low19.06% ATR0.45
Employees99827 Current Ratio0.90 Sales Q/Q18.50% Oper. Margin12.40% RSI (14)64.86 Volatility0.87% 0.84%
OptionableYes Debt/Eq10.70 EPS Q/Q271.90% Profit Margin5.80% Rel Volume0.66 Prev Close44.16
ShortableYes LT Debt/Eq8.52 EarningsJul 26 Payout232.70% Avg Volume3.00M Price44.29
Recom2.00 SMA201.41% SMA503.85% SMA2007.92% Volume1,981,144 Change0.29%
May-26-17Upgrade Berenberg Hold → Buy
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Jun-22-17 05:17PM  GSK's new CEO aims to divest sports nutrition brand: sources Reuters
10:06AM  Glaxo's (GSK) Shingles Candidate Phase III Data Positive Zacks
08:08AM  Early movers: ORCL, HAIN, ACN, SCS, ATUS, NVS, GSK & more CNBC
Jun-21-17 06:41PM  GSK wins $235 million from Teva in Coreg patent trial Reuters
03:00PM  Amgen An Undervalued Industry Leader Forbes
11:19AM  GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting PR Newswire
Jun-20-17 02:06PM  Dupixent May Prove Effective in Multiple Diseases Market Realist
12:20PM  Label Expansion May Boost Regenerons Dupixent in the Future Market Realist
Jun-19-17 04:56PM  Novartis (NVS) Biosimilar of MabThera Approved in the EU Zacks
12:26PM  GSK's new pharma head to join in September after AstraZeneca tussle Reuters
10:21AM  GlaxoSmithKline's Benlysta Positive in Continuation Trial Zacks
Jun-18-17 11:42AM  5 Answers to Questions Gilead Sciences' Investors Probably Have Motley Fool
Jun-16-17 09:45AM  Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now? Zacks
Jun-09-17 06:22PM  Why GlaxoSmithKline Stock Had a Breakout May Motley Fool
04:45PM  Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma Motley Fool
08:46AM  Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises Zacks
Jun-07-17 07:02PM  [$$] Four innovators help to improve healthcare access for the poor Financial Times
08:38AM  2 High-Yield Dividend Stocks That Might Be Incredible Bargains Right Now Motley Fool
Jun-06-17 06:12PM  Novartis, Bristol-Myers Collaborate for Opdivo Combination Zacks
12:06PM  2 giant drugmakers are racing to make a breakthrough in treating HIV, and there's $22 billion on the line Business Insider
Jun-02-17 05:08AM  GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment
Jun-01-17 04:15PM  Deed records reveal sale price, billionaire buyer of GSKs RTP campus American City Business Journals
09:08AM  GlaxoSmithKlines Vaccines Segment in 1Q17 Market Realist
07:38AM  What Happened to Novartiss Valuation after 1Q17? Market Realist
07:38AM  GlaxoSmithKlines Pharmaceuticals Segment in 1Q17 Market Realist
May-31-17 05:35PM  GlaxoSmithKlines Segment Performances in 1Q17 Market Realist
04:04PM  How GlaxoSmithKlines Valuation Changed after 1Q17 Market Realist
03:44PM  3 Top Dividend Stocks in Diabetes Treatment Motley Fool
03:17PM  GlaxoSmithKline Surges to New Highs
12:30PM  European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data
May-30-17 04:21PM  Gilead's HIV Combo Passes Muster, But Can It Stand Up To Glaxo, Merck? Investor's Business Daily
04:20PM  Medtronic, GlaxoSmithKline team up in $40M equity deal for back-pain startup American City Business Journals
11:21AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
10:21AM  GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead
09:37AM  Gilead's HIV drug meets goal in four late-stage studies Reuters
09:30AM  The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories Zacks
May-26-17 05:44PM  [$$] GSK among biggest gainers as weak pound lifts FTSE 100 Financial Times
04:23PM  Genvoya Could Drive Gilead Sciences Revenue Growth in 2017 Market Realist
12:44PM  Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others Zacks
11:06AM  GlaxoSmithKline's New CEO Is Off to a Good Start Motley Fool
04:30AM  FTSE 100 at all-time high, with the pound knocked below $1.29 MarketWatch
May-24-17 09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
May-23-17 08:14AM  A Close Look at Merck & Co.s Valuation after 1Q17 Earnings Market Realist
May-21-17 06:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. Motley Fool
May-16-17 05:57PM  Ionis (IONS) Stock Falls Despite Positive Inotersen Data Zacks
11:15AM  Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns Benzinga
08:00AM  Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis Accesswire
May-15-17 08:27AM  GlaxoSmithKline Could Buy Out Partner Novartis
May-12-17 11:56AM  Top-10 Glaxo investor Woodford sells out, criticises board Reuters
09:59AM  Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'
08:05AM  Woodford Turns Bullish on Lloyds as He Cuts Ties With Glaxo Bloomberg
May-11-17 03:16PM  [$$] SuperGroup's wholesale change translates into sales Financial Times
03:38AM  Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval
May-10-17 03:25PM  Mylan disagrees with FDA over generic Advair delay Reuters
01:25PM  GlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017 Capital Cube
12:28PM  Better Buy: GlaxoSmithKline vs. Johnson & Johnson Motley Fool
11:37AM  Mylan says disagrees with FDA over generic Advair delay Reuters
10:59AM  FTSE 100 flirts with 7-week high as oil shares climb MarketWatch
May-09-17 09:50AM  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1 Zacks
May-06-17 07:25AM  Which Big Pharma Is the Best Dividend Stock? Motley Fool
May-05-17 01:12PM  Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1 Zacks
08:23AM  GSK 'real world' drug test has second success in asthma Reuters
07:38AM  Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care Business Wire
May-04-17 07:40AM  Here's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April Motley Fool
May-03-17 07:36AM  Whats GlaxoSmithKlines Valuation after 1Q17 Earnings? Market Realist
May-02-17 11:10AM  Cambridge's bluebird bio licenses delivery tech to Novartis, GSK American City Business Journals
10:36AM  How GlaxoSmithKlines Consumer Healthcare Segment Fared in 1Q17 Market Realist
09:07AM  How GlaxoSmithKlines Vaccines Business Performed in 1Q17 Market Realist
07:38AM  Analyzing GlaxoSmithKlines Global Pharmaceutical Performance Market Realist
May-01-17 03:57PM  ETFs with exposure to GlaxoSmithKline Plc : May 1, 2017 Capital Cube
01:41PM  3 Bargain-Bin High-Yield Dividend Stocks You've Overlooked This Spring Motley Fool
12:36PM  GlaxoSmithKline making $139M investment in Rockville plant American City Business Journals
11:30AM  Triad college awarded $25,000 STEM grant American City Business Journals
10:39AM  How Did GlaxoSmithKlines HIV Business Perform in 1Q17? Market Realist
09:42AM  Is This Big Pharma Stock's Sky-High Dividend Yield Sustainable? Motley Fool
09:09AM  How Did GlaxoSmithKlines Pharmaceuticals Segment Do in 1Q17? Market Realist
07:40AM  How GlaxoSmithKlines Business Segments Performed in 1Q17 Market Realist
07:37AM  Novartiss Valuation after 1Q17 Earnings Market Realist
Apr-28-17 04:45PM  GlaxoSmithKlines 1Q17 Earnings Surpass Analysts Estimates Market Realist
11:12AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Capital Cube
Apr-27-17 04:37PM  Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View Zacks
12:05AM  New Glaxo Boss Emma Walmsley Seeks Sharper R&D Edge The Wall Street Journal
Apr-26-17 10:55AM  New GlaxoSmithKline CEO wants fewer, bigger new drug launches Reuters
10:36AM  Analyst Ratings and Recommendations for GlaxoSmithKline Market Realist
10:26AM  Glaxo meets 1Q profit forecasts Associated Press
10:01AM  Ionis Pharmaceuticals: Big Data Coming Soon Motley Fool
09:46AM  Glaxo Stock Slumps as Investors Eye Advair Generics
09:11AM  Glaxo (GSK) Beats Earnings and Revenues in Q1 Zacks
09:07AM  GlaxoSmithKlines 1Q17 Estimates: Consumer Healthcare Market Realist
08:57AM  GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place
08:31AM  GSK warns of impact from generic drugs after solid Q1 Associated Press
08:25AM  [$$] GlaxoSmithKline Net Income Boosted by Strong Sales, Weak Pound The Wall Street Journal
07:36AM  GlaxoSmithKlines 1Q17 Estimates: Vaccines Business Market Realist
07:13AM  Glaxo's New CEO Walmsley Pledges to Make Drugs the Priority Bloomberg
07:13AM  Glaxo Profit Jumps 31% as Sales of HIV, Lung Drugs Increase Bloomberg
07:10AM  Weak sterling boosts GlaxSmithKline as new CEO takes over Reuters
Apr-25-17 03:01PM  [$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound The Wall Street Journal
10:39AM  GlaxoSmithKlines 1Q17 Estimates: Pharmaceuticals Segment Market Realist
09:09AM  GlaxoSmithKlines 1Q17 Estimates: Revenues Expected to Grow Market Realist
07:40AM  GlaxoSmithKlines 1Q17 Earnings: Analysts Estimates Market Realist
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM